ArticleCureus2025
Development of Age-Related Macular Degeneration During Treatment for Diabetic Macular Edema: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a rare case of a patient who developed age-related macular degeneration (AMD) in one eye during treatment of diabetic macular edema (DME) in both eyes. A 70-year-old man was followed for diabetic retinopathy for 23 years. At his initial visit in 200X, his decimal visual acuity was 1.0 in both eyes. He underwent panretinal photocoagulation for pre-proliferative diabetic retinopathy (PPDR) in both eyes. Optical coherence tomography (OCT), which was done nine years after the initial visit, revealed a small retinal pigment epithelial detachment (PED) in the left eye. Sixteen years after the initial visit, he developed DME in his right eye and an epiretinal membrane (ERM) in his left eye. Seventeen years after the initial visit, he developed DME in his left eye, and he was treated with sub-tenon triamcinolone acetonide (STTA) injections in the right eye. The STTA was not effective, and we switched to anti-vascular endothelial growth factor (anti-VEGF) injections for both eyes. The anti-VEGF injections were performed 22 times (aflibercept, IVA 12 times; faricimab, IVF 10 times) in the right eye for the DME. His decimal visual acuity fluctuated between 0.2 and 0.9 during this period. The left eye underwent pars plana vitrectomy (PPV) for the DME and ERM 17 years after the initial visit. Although the macular edema was resolved, subretinal fluid and macular neovascularization (MNV) appeared 22 years after the initial visit. Since then, IVF has been performed 10 times, and the decimal visual acuity has improved from 0.4 to 0.8. He underwent bilateral cataract surgery 17 years after the initial visit. Twenty-two years after the initial visit, the left eye developed MNV, located near the PED that had been seen on the OCT image taken 13 years earlier. The relationships of the ERM, DME, and PPV with MNV were not determined. At present, both eyes are responding well to the IVF treatments. This case will remind clinicians of the possibility of the two diseases coexisting and will lead to a better understanding of the pathogenic mechanisms of both diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.